Pulmonary Biomarker Surfactant Protein-B Is Used for Diagnosis
By LabMedica International staff writers Posted on 10 Dec 2008 |
Roche Diagnostics (Rotkreuz, Switzerland) and an Australian Biotech company, Southern Medical Diagnostics (SMD; Walkerville, Australia) signed licensing agreements on diagnostic applications of Surfactant Protein-B.
According to the agreements, Roche will have semi-exclusive worldwide rights for diagnostic applications of Surfactant Protein-B (SP-B) in lung disorders; SMD will have worldwide rights to key test-components developed by Roche, which SMD may exclusively use for SP-B applications.
A lung-specific protein and a key functional component of the alveolus, SP-B is present at very low concentrations in the serum of healthy people. It is released into the blood stream as a result of lung injury and is significantly increased in primary and secondary lung disorders affecting mainly the lung parenchyma. This includes the alveolocapillary system, such as chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), and heart failure. Changes of lung disorders can be monitored by measuring levels of SP-B in the blood.
Together with B-type natriuretic peptide (BNP or NT-proBNP) tests, SP-B helps to discriminate between cardiac and non-cardiac causes of dyspnea.
"Roche Diagnostics believes that tests for Surfactant Protein-B will be very valuable in the diagnosis, differential diagnosis, and monitoring of patients with primary and secondary pulmonary disorders," said Dirk Ehlers, head of Roche Professional Diagnostics." He added, "The SP-B assay will allow earlier recognition of cardio-pulmonary conditions and thereby prepare the basis for improved treatment in the future."
Roche is one of the world's leading healthcare groups in the fields of diagnostics and pharmaceutics. The company is a world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology.
Southern Medical Diagnostics Pty Ltd. is a private Australian company specializing in the development and out-licensing of novel diagnostic technologies.
Related Links:
Roche Diagnostics
Southern Medical Diagnostics
According to the agreements, Roche will have semi-exclusive worldwide rights for diagnostic applications of Surfactant Protein-B (SP-B) in lung disorders; SMD will have worldwide rights to key test-components developed by Roche, which SMD may exclusively use for SP-B applications.
A lung-specific protein and a key functional component of the alveolus, SP-B is present at very low concentrations in the serum of healthy people. It is released into the blood stream as a result of lung injury and is significantly increased in primary and secondary lung disorders affecting mainly the lung parenchyma. This includes the alveolocapillary system, such as chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), and heart failure. Changes of lung disorders can be monitored by measuring levels of SP-B in the blood.
Together with B-type natriuretic peptide (BNP or NT-proBNP) tests, SP-B helps to discriminate between cardiac and non-cardiac causes of dyspnea.
"Roche Diagnostics believes that tests for Surfactant Protein-B will be very valuable in the diagnosis, differential diagnosis, and monitoring of patients with primary and secondary pulmonary disorders," said Dirk Ehlers, head of Roche Professional Diagnostics." He added, "The SP-B assay will allow earlier recognition of cardio-pulmonary conditions and thereby prepare the basis for improved treatment in the future."
Roche is one of the world's leading healthcare groups in the fields of diagnostics and pharmaceutics. The company is a world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology.
Southern Medical Diagnostics Pty Ltd. is a private Australian company specializing in the development and out-licensing of novel diagnostic technologies.
Related Links:
Roche Diagnostics
Southern Medical Diagnostics
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans